PB-1023 is under clinical development by PhaseBio Pharmaceuticals and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect PB-1023’s likelihood of approval (LoA) and phase transition for Sarcopenia took place on 27 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their PB-1023 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

PB-1023 overview

PB-1023 is under development for the treatment of duchenne muscular dystrophy, becker muscular dystrophy, polymyositis, senile sarcopenia and inclusion body myositis. The drug candidate is is a long acting glucagon like peptide-1 (GLP-1) elastin like peptide (ELP)-120 fusion protein acts by targeting glucagon-like peptide 1 receptor (GLP1R). 

It was also under the  development for the treatment of hyperglycemia associated with type 2 diabetes.

PhaseBio Pharmaceuticals overview

PhaseBio Pharmaceuticals (PhaseBio) is a clinical-stage biopharmaceutical company that develops biotherapeutics for the treatment of orphan diseases and cardiopulmonary indications. The company’s pipeline products include PB2452, a novel recombinant human monoclonal antibody antigen-binding fragment, designed to reverse the antiplatelet activity of ticagrelor; PB1046 is a subcutaneously-injected, sustained release analogue of the native human peptide vasoactive intestinal peptide (VIP) used for the treatment of pulmonary arterial hypertension. PhaseBio proprietary ELP Biopolymer technology platform extends the circulating half-life of proteins and peptides and also provides a sustained-release mechanism for periods of a week or longer from a single subcutaneous injection. The company develops drugs for the treatment of endocrine, metabolic and cardiovascular diseases. PhaseBio is headquartered in Malvern, Pennsylvania, the United States.

Quick View PB-1023 LOA Data

Report Segments
  • Innovator
Drug Name
  • PB-1023
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Genetic Disorders
  • Metabolic Disorders
  • Musculoskeletal Disorders
Key Developers
  • Sponsor Company: PhaseBio Pharmaceuticals
  • Originator: PhaseBio Pharmaceuticals
Highest Development Stage
  • Phase I


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.